Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0A8CG
|
||||
| Former ID |
DCL000273
|
||||
| Drug Name |
Lonapalene
|
||||
| Synonyms |
Lonapaleno; Lonapalenum; Lonapaleno [Spanish]; Lonapalenum [Latin]; RS 43179; Lonapalene (USAN); RS-43179; (4-acetyloxy-6-chloro-2,3-dimethoxynaphthalen-1-yl) acetate; 6-Chloro-2,3-dimethoxy-1,4-naphthalenediol diacetate
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Psoriasis [ICD9: 696; ICD10:L40] | Discontinued in Phase 3 | [1] | ||
| Company |
Bristol-Myers Squibb
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C16H15ClO6
|
||||
| Canonical SMILES |
CC(=O)OC1=C(C(=C(C2=C1C=CC(=C2)Cl)OC(=O)C)OC)OC
|
||||
| InChI |
1S/C16H15ClO6/c1-8(18)22-13-11-6-5-10(17)7-12(11)14(23-9(2)19)16(21-4)15(13)20-3/h5-7H,1-4H3
|
||||
| InChIKey |
IFWMVQUGSGWCRP-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 91431-42-4
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Arachidonate 5-lipoxygenase | Target Info | Inhibitor | [2], [3] | |
| BioCyc Pathway | Aspirin-triggered lipoxin biosynthesis | ||||
| Resolvin D biosynthesis | |||||
| Leukotriene biosynthesis | |||||
| Lipoxin biosynthesis | |||||
| Aspirin triggered resolvin D biosynthesis | |||||
| Aspirin triggered resolvin E biosynthesis | |||||
| KEGG Pathway | Arachidonic acid metabolism | ||||
| Metabolic pathways | |||||
| Serotonergic synapse | |||||
| Ovarian steroidogenesis | |||||
| Toxoplasmosis | |||||
| NetPath Pathway | IL4 Signaling Pathway | ||||
| PathWhiz Pathway | Arachidonic Acid Metabolism | ||||
| WikiPathways | Vitamin D Receptor Pathway | ||||
| Arachidonic acid metabolism | |||||
| Eicosanoid Synthesis | |||||
| Selenium Micronutrient Network | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003802) | ||||
| REF 2 | Preview of potential therapeutic applications of leukotriene B4 inhibitors in dermatology. Skin Pharmacol Appl Skin Physiol. 2000 Sep-Oct;13(5):235-45. | ||||
| REF 3 | Pharmacologic and clinical effects of lonapalene (RS 43179), a 5-lipoxygenase inhibitor, in psoriasis. J Invest Dermatol. 1990 Jul;95(1):50-4. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.